Literature DB >> 19751543

CRF receptor blockade prevents initiation and consolidation of stress effects on affect in the predator stress model of PTSD.

Robert Adamec1, Dennis Fougere, Victoria Risbrough.   

Abstract

Post traumatic stress disorder (PTSD) is a chronic anxiety disorder initiated by an intensely threatening, traumatic event. There is a great need for more efficacious pharmacotherapy and preventive treatments for PTSD. In animals, corticotropin-releasing factor (CRF) and the CRF1 receptor play a critical role in behavioural and neuroendocrine responses to stress. We tested the hypothesis that CRF1 activation is required for initiation and consolidation of long-term effects of trauma on anxiety-like behaviour in the predator exposure (predator stress) model of PTSD. Male C57BL6 mice were treated with the selective CRF1 antagonist CRA0450 (2, 20 mg/kg) 30 min before or just after predator stress. Long-term effects of stress on rodent anxiety were measured 7 d later using acoustic startle, elevated plus maze (EPM), light/dark box, and hole-board tests. Predator stress increased startle amplitude and delayed startle habituation, increased time in and decreased exits from the dark chamber in the light/dark box test, and decreased risk assessment in the EPM. CRF1 antagonism had limited effects on these behaviours in non-stressed controls, with the high dose decreasing risk assessment in the EPM. However, in stressed animals CRF1 antagonism blocked initiation and consolidation of stressor effects on startle, and returned risk assessment to baseline levels in predator-stressed mice. These findings implicate CRF1 activation in initiation and post-trauma consolidation of predator stress effects on anxiety-like behaviour, specifically on increased arousal as measured by exaggerated startle behaviours. These data support further research of CRF1 antagonists as potential prophylactic treatments for PTSD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19751543      PMCID: PMC3092595          DOI: 10.1017/S1461145709990496

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  58 in total

1.  Prophylactic and therapeutic effects of acute systemic injections of EMD 281014, a selective serotonin 2A receptor antagonist on anxiety induced by predator stress in rats.

Authors:  Robert Adamec; Katherine Creamer; Gerd D Bartoszyk; Paul Burton
Journal:  Eur J Pharmacol       Date:  2004-11-03       Impact factor: 4.432

2.  Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication.

Authors:  Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Kathleen R Merikangas; Ellen E Walters
Journal:  Arch Gen Psychiatry       Date:  2005-06

Review 3.  Transmitter systems involved in neural plasticity underlying increased anxiety and defense--implications for understanding anxiety following traumatic stress.

Authors:  R Adamec
Journal:  Neurosci Biobehav Rev       Date:  1997-11       Impact factor: 8.989

4.  The effect of lateral septum corticotropin-releasing factor receptor 2 activation on anxiety is modulated by stress.

Authors:  Brook Henry; Wylie Vale; Athina Markou
Journal:  J Neurosci       Date:  2006-09-06       Impact factor: 6.167

5.  Long-lasting, selective, anxiogenic effects of feline predator stress in mice.

Authors:  Robert Adamec; Sue Walling; Paul Burton
Journal:  Physiol Behav       Date:  2004-12-15

6.  Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene.

Authors:  Avshalom Caspi; Karen Sugden; Terrie E Moffitt; Alan Taylor; Ian W Craig; HonaLee Harrington; Joseph McClay; Jonathan Mill; Judy Martin; Antony Braithwaite; Richie Poulton
Journal:  Science       Date:  2003-07-18       Impact factor: 47.728

7.  Corticotropin-releasing factor in posttraumatic stress disorder (PTSD) with secondary psychotic symptoms, nonpsychotic PTSD, and healthy control subjects.

Authors:  Frederic J Sautter; Garth Bissette; Justin Wiley; Gina Manguno-Mire; Benjamin Schoenbachler; Leann Myers; Janet E Johnson; Arleen Cerbone; Dolores Malaspina
Journal:  Biol Psychiatry       Date:  2003-12-15       Impact factor: 13.382

8.  Changes in brain cholecystokinin and anxiety-like behavior following exposure of mice to predator odor.

Authors:  A L O Hebb; R M Zacharko; H Dominguez; S Laforest; M Gauthier; C Levac; G Drolet
Journal:  Neuroscience       Date:  2003       Impact factor: 3.590

9.  Anxiolytic- and antidepressant-like profile of a new CRF1 receptor antagonist, R278995/CRA0450.

Authors:  Shigeyuki Chaki; Atsuro Nakazato; Ludo Kennis; Masato Nakamura; Claire Mackie; Masayuki Sugiura; Petra Vinken; David Ashton; Xavier Langlois; Thomas Steckler
Journal:  Eur J Pharmacol       Date:  2004-02-06       Impact factor: 4.432

10.  Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development.

Authors:  G W Smith; J M Aubry; F Dellu; A Contarino; L M Bilezikjian; L H Gold; R Chen; Y Marchuk; C Hauser; C A Bentley; P E Sawchenko; G F Koob; W Vale; K F Lee
Journal:  Neuron       Date:  1998-06       Impact factor: 17.173

View more
  27 in total

Review 1.  Molecular and cell signaling targets for PTSD pathophysiology and pharmacotherapy.

Authors:  Richard L Hauger; J Alberto Olivares-Reyes; Frank M Dautzenberg; James B Lohr; Sandra Braun; Robert H Oakley
Journal:  Neuropharmacology       Date:  2011-11-25       Impact factor: 5.250

Review 2.  Prevention of Trauma and Stressor-Related Disorders: A Review.

Authors:  Jonathon R Howlett; Murray B Stein
Journal:  Neuropsychopharmacology       Date:  2015-08-28       Impact factor: 7.853

3.  Susceptibility to PTSD-like behavior is mediated by corticotropin-releasing factor receptor type 2 levels in the bed nucleus of the stria terminalis.

Authors:  Maya Lebow; Adi Neufeld-Cohen; Yael Kuperman; Michael Tsoory; Shosh Gil; Alon Chen
Journal:  J Neurosci       Date:  2012-05-16       Impact factor: 6.167

4.  Enduring sensorimotor gating abnormalities following predator exposure or corticotropin-releasing factor in rats: a model for PTSD-like information-processing deficits?

Authors:  Vaishali P Bakshi; Karen M Alsene; Patrick H Roseboom; Elenora E Connors
Journal:  Neuropharmacology       Date:  2011-02-01       Impact factor: 5.250

5.  Sex differences in neurosteroid and hormonal responses to metyrapone in posttraumatic stress disorder.

Authors:  Sabra S Inslicht; Anne Richards; Erin Madden; Madhu N Rao; Aoife O'Donovan; Lisa S Talbot; Evelyn Rucker; Thomas J Metzler; Richard L Hauger; Thomas C Neylan
Journal:  Psychopharmacology (Berl)       Date:  2014-06-21       Impact factor: 4.530

Review 6.  Pharmacological treatment of PTSD - established and new approaches.

Authors:  Thomas Steckler; Victoria Risbrough
Journal:  Neuropharmacology       Date:  2011-06-29       Impact factor: 5.250

7.  Corticotropin-releasing factor and noradrenergic signalling exert reciprocal control over startle reactivity.

Authors:  Jodi E Gresack; Victoria B Risbrough
Journal:  Int J Neuropsychopharmacol       Date:  2010-12-21       Impact factor: 5.176

8.  Forebrain-specific CRF overproduction during development is sufficient to induce enduring anxiety and startle abnormalities in adult mice.

Authors:  Mate Toth; Jodi E Gresack; Debra A Bangasser; Zach Plona; Rita J Valentino; Elizabeth I Flandreau; Isabelle M Mansuy; Emilio Merlo-Pich; Mark A Geyer; Victoria B Risbrough
Journal:  Neuropsychopharmacology       Date:  2013-12-11       Impact factor: 7.853

Review 9.  The predator odor avoidance model of post-traumatic stress disorder in rats.

Authors:  Lucas Albrechet-Souza; Nicholas W Gilpin
Journal:  Behav Pharmacol       Date:  2019-04       Impact factor: 2.293

Review 10.  Recent progress in understanding the pathophysiology of post-traumatic stress disorder: implications for targeted pharmacological treatment.

Authors:  Christopher R Bailey; Elisabeth Cordell; Sean M Sobin; Alexander Neumeister
Journal:  CNS Drugs       Date:  2013-03       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.